Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
- Conditions
- HIV
- Interventions
- Biological: 16055 NFL delta Gly4 trimerBiological: Ad4-Env145NFL, 5 x 108 viral particles (vp)
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 45
- Registration Number
- NCT06332339
- Locations
- ๐บ๐ธ
Alabama CRS, Birmingham, Alabama, United States
๐บ๐ธBrigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
๐บ๐ธThe Hope Clinic of the Emory Vaccine Center CRS Site# 31440, Decatur, Georgia, United States
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- Conditions
- Chronic Granulomatous Disease (CGD)X-Linked Chronic Granulomatous Disease
- Interventions
- Biological: Base-edited hematopoietic stem and progenitor cells
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-05-16
- Target Recruit Count
- 1
- Registration Number
- NCT06325709
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
- Conditions
- Liver Transplant
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-03-18
- Target Recruit Count
- 340
- Registration Number
- NCT06280950
- Locations
- ๐บ๐ธ
Mayo Clinic Hospital Arizona (Site #: 71144), Phoenix, Arizona, United States
๐บ๐ธUniversity of California, San Francisco (Site #: 71108), San Francisco, California, United States
๐บ๐ธNorthwestern University (Site #: 71110), Chicago, Illinois, United States
A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-03-26
- Target Recruit Count
- 42
- Registration Number
- NCT06267872
- Locations
- ๐บ๐ธ
Alabama CRS (Site ID: 31788), Birmingham, Alabama, United States
๐บ๐ธThe Ponce de Leon Center CRS (Site ID: 5802), Atlanta, Georgia, United States
๐บ๐ธVanderbilt Vaccine (VV) CRS (Site ID: 30352), Nashville, Tennessee, United States
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
- Conditions
- p47Autosomal RecessiveChronic Granulomatous Disease
- Interventions
- Biological: Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 10
- Registration Number
- NCT06253507
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- ๐ง๐ผ
12701, Gaborone CRS, Gaborone, Botswana
๐ง๐ท12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil
๐ง๐ท12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
- Conditions
- Nervous System DiseaseImmune System Disease
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-10-04
- Target Recruit Count
- 350
- Registration Number
- NCT06169150
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-11-22
- Target Recruit Count
- 256
- Registration Number
- NCT06153979
- Locations
- ๐ฒ๐ฑ
University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
๐ฌ๐ณPartnership of Clinical Research in Guinea, Partenariat Pour La Recherche Clinique en Guinรฉe (PREGUI), Conakry, Guinea
Safety Study of SLV213 for the Treatment of COVID-19.
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 16
- Registration Number
- NCT06146374
- Locations
- ๐บ๐ธ
Altasciences Inc - Kansas City, Overland Park, Kansas, United States
Protocol CAUSE-03 / CHEETAH
- Conditions
- Asthma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 310
- Registration Number
- NCT06136091
- Locations
- ๐บ๐ธ
Children's Hospital Colorado: Allergy Program, Aurora, Colorado, United States
๐บ๐ธChildren's National Medical Center: Children's Research Institute, Washington, District of Columbia, United States
๐บ๐ธBoston University School of Medicine: Pulmonary Center, Boston, Massachusetts, United States